1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. AXSOME THERAPEUTICS INC
Axsome Therapeutics Inc
XNAS: AXSM
Momentum Trap
Download real time
156.32-9.68(-5.83%)
39.92% Fall from 52W High
1.3M
XNAS Volume

XNAS 13 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Axsome Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Axsome Therapeutics Inc share price target, revenues, EPS, net income and more

Axsome Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • POSITIVE

    Quarterly Revenue Axsome Therapeutics Inc Jun-2026 Quarterly Revenue is $218 Million which is growth of 45.5% YoY.

  • NEGATIVE

    Quarterly Net Profit Axsome Therapeutics Inc Jun-2026 Quarterly Net Profit is $-51 Million which is growth of -7.0% YoY.

Axsome Therapeutics Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
218.4191.2196171150121.5118.8104.887.27571.557.846.7
Cost Of Rev.
13.614.712.311.913.59.810.58.48.16.37.46.54.6
Gross Profit
204.8176.5183.7159.1136.6111.7108.396.379.168.764.251.342.1
⌄
256239.2219.7192181.4167.1169.9142.6155137.4119.2113.6101.1
Operating Profit
-51.1-62.8-36-32.9-44.8-55.5-61.6-46.2-75.9-68.7-55.1-62.3-59
⌄
-1.5-1.2-1.2-1.1-1.8-2.4-2.2-2-1.3-1.1-0.7-0.8-2.7
Profit Before Tax
-51.2-64.5-28.1-47.2-48.9-59.4-74.8-64.6-79.3-68.4-99-62.9-67.8
Tax
0.10.4-10.1-0.3-0.7-0.6
⌄
-51.3-64.5-28.6-47.2-48-59.4-74.9-64.6-79.3-68.4-98.7-62.2-67.2
Diluted NI Avail to Com Stockholders Ann.
-51.3-64.5-28.6-47.2-48-59.4-74.9-64.6-79.3-68.4-98.7-62.2-67.2
Basic EPS
-1-1.3-0.6-0.9-1-1.2-1.5-1.3-1.7-1.4-2.1-1.3-1.5
Diluted EPS After ExtraOrdinary
-1-1.3-0.7-0.7-0.9-1.2-1.4-1-1.6-1.5-1.2-1.3-1.4
Number Of Shares End
51.851.250.65049.448.948.648.147.647.447.447.143.7
Net Income Continuing Discontinued Operations
-51.3-64.5-28.6-47.2-48-59.4-74.9-64.6-79.3-68.4-98.7-62.2-67.2
Normalized Income
-31.1-40.5-17.8-10.9-21.6-34.6-48.9-26.6-55.8-49.6-36.7-47.7-45.4
Interest Income
-------------
Interest
1.51.21.21.11.82.42.221.31.10.70.82.7
Net Interest Income
-1.5-1.2-1.2-1.1-1.8-2.4-2.2-2-1.3-1.1-0.7-0.8-2.7
EBIT
-49.7-63.4-27-46.1-47.1-57-72.6-62.6-78.1-67.3-98.3-62.1-65.1
EBITDA
-46.8-61-24.7-43.7-44.9-54.9-70.5-60.6-76.1-65.4-96.5-60.4-63.7
Reconciled Cost Of Rev.
12.313.911.711.112.89.210.187.76.17.36.44.8
Reconciled Depr.
2.92.42.32.42.32.12.12.121.81.71.71.4
Profit From Continuing Operations
-51.3-64.5-28.6-47.2-48-59.4-74.9-64.6-79.3-68.4-98.7-62.2-67.2
Normalized EBITDA
-48.3-60.4-33.8-30.5-42.6-53.3-59.6-44.2-73.9-66.9-53.3-60.6-57.4
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Axsome Therapeutics Inc competitor comparison and performance snapshot within industry

Axsome Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Annual Revenue Axsome Therapeutics Inc Dec-2025 Annual Revenue is $638 Million which is growth of 65.5% YoY.

  • POSITIVE

    Annual Net Profit Axsome Therapeutics Inc Dec-2025 Annual Net Profit is $-183 Million which is growth of 36.2% YoY.

Axsome Therapeutics Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
133.7%
-
 638.5385.7270.650
Cost Of Rev. Ann.
109%
-
52.547.533.326.15.2-------
Gross Profit Ann.
136.3%
-
724591352.4244.544.8-------
Operating Exp. Ann.
50.9%
50.3%
906.9760.3604.8427.4221.3124.799.167.132.62727.19.2
Operating Profit Ann.
-
-
-182.9-169.2-252.4-182.9-176.5-124.7-99.1-67.1-32.6-27-27.1-9.2
⌄
-
-
-5-6.6-6.6-6.5-7.3-5.7-2.6-1.2-1.1-1.3-0.10.9
Other Exp. Ann.
-
-
 -7.9-28.1-48.9-3.3--1.3-2.8-0.7--2.3
PBT Ann.
-
-
-191.1-183.7-287.1-238.3-187.1-130.4-102.9-68.4-31-28.9-27.2-10.6
Tax Ann.
-
-
0.6-0.50.11--------
⌄
-
-
-191.6-183.2-287.2-239.2-187.1-130.4-102.9-68.4-31-28.9-27.2-10.6
Diluted NI Avail to Com Stockholders Ann.
-
-
-191.6-183.2-287.2-239.2-187.1-130.4-102.9-68.4-31-28.9-27.2-10.6
EPS Ann.
-
-
 -3.7-6-5.3-4.6-3.5-2.8-2-1.2-1.3-1.4-0.9
Diluted EPS Ann.
-
-
 -3.7-6-5.3-4.6-3.5-2.8-2-1.2-1.3-1.4-0.9
Number Of Shares End
5.2%
6.2%
 50.648.647.443.537.837.434.829.924.319.29.6
Total Exp. Ann.
52.8%
52.1%
 807.7638.1453.5226.5124.799.167.132.62727.19.2
Net Income Continuing Discontinued Operations Ann.
-
-
-191.6-183.2-287.2-239.2-187.1-130.4-102.9-68.4-31-28.9-27.2-10.6
Normalized Income Ann.
-
-
-100.3-81.8-197.7-151.1-146.1-109.6-86.9-62.2-32-26.2-25.2-7.5
Interest Income Ann.
-
-
 ----------0.9
Interest Ann.
-3.3%
20.5%
56.66.66.57.35.72.61.21.11.30.1-
EBITDA Ann.
-
-
-176.1-168.1-272.6-225-174.2-123.6-100.3-67.1-29.8-27.6-27.1-11.5
Reconciled Cost Of Rev. Ann.
127.6%
-
4944.831.725.63.8-------
Reconciled Depr. Ann.
17.6%
146.5%
9.99.186.85.61.20.100.100
Profit From Continuing Operations Ann.
-
-
-191.6-183.2-287.2-239.2-187.1-130.4-102.9-68.4-31-28.9-27.2-10.6
Normalized EBITDA Ann.
-
-
-172.9-160.2-244.5-176.1-170.9-123.6-99-67.1-32.6-26.9-27.1-6.9
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
65.5%
2Y CAGR
53.6%
3Y CAGR
133.7%
Operating Exp. Ann.
1Y CHG
25.7%
2Y CAGR
33.4%
3Y CAGR
50.9%
5Y CAGR
50.3%
7Y CAGR
56.8%
10Y CAGR
55.5%
Operating Expenses Annual Cr growth is lower than historical averages.

Axsome Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Axsome Therapeutics Inc Dec-2025 Total Shareholders Fund is $88 Million which is growth of 54.9% YoY.

  • POSITIVE

    Total Assets Axsome Therapeutics Inc Dec-2025 Total Assets is $690 Million which is growth of 21.3% YoY.

Axsome Therapeutics Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
27.7%
30%
689.8568.5588.2331.587.8186.1220.615.435.638.249.1
⌄
39.4%
52.8%
601.5511.5397.3221.972.272.341.814.418.816.62.6
⌄
-6.9%
-4.9%
88.357191109.615.6113.8178.70.916.721.646.4
Total Capitalization Ann.
0.4%
4.9%
206237.7369.1203.864.7162.1196.14.623.43146.4
Tangible Assets Ann.
-3.4%
-20.7%
35.7-1.9125.739.615.6113.8178.70.916.721.646.4
Working Capital Ann.
12.1%
5.5%
210.2255365.4149.163.5160.6195.94.423.130.846.4
Invested Capital Ann.
10.6%
11.2%
276237.7369.1203.864.7162.1198.77.926.731.346.4
Tangible Book Value Ann.
-3.4%
-20.7%
35.7-1.9125.739.615.6113.8178.70.916.721.646.4
Borrowings Ann.
32.1%
34.2%
218.1193186.494.749.750.119.96.99.99.7-
Net Debt Ann.
-
-
-----------
Share Issued Ann.
5.4%
6.4%
50.948.747.443.537.837.436.930.125.519.219.2
Number Of Shares End
5.2%
6.2%
50.648.647.443.537.837.434.829.924.319.29.6
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
21.3%
2Y CAGR
8.3%
3Y CAGR
27.7%
5Y CAGR
30%
7Y CAGR
72.1%
10Y CAGR
30.2%
Total Assets Annual growth is lower than historical averages.
Total Current Liabilities Ann.
1Y CHG
64.6%
2Y CAGR
65.1%
3Y CAGR
57.7%
5Y CAGR
74.5%
7Y CAGR
66.2%
10Y CAGR
64.6%
Total Current Liabilities Annual Cr growth is stable compared to historical averages.
Total ShareHolders Funds Ann.
1Y CHG
54.9%
2Y CAGR
-32%
3Y CAGR
-6.9%
5Y CAGR
-4.9%
7Y CAGR
92.5%
10Y CAGR
6.6%
Total ShareHolders Funds Annual growth is stable compared to historical averages.

Axsome Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share Axsome Therapeutics Inc Book Value Per Share is $2 which is growth of 47.6% YoY.

  • NEUTRAL

    ROE Axsome Therapeutics Inc ROE is 0% which is growth of 0% YoY.

Axsome Therapeutics Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
--49.66%-52.02%-89.27%-95.21%-50.60%-57.94%-121.59%-78.47%-62.33%-40.72%
ROE Ann. %
-
-
--231.63%-159.21%-298.97%-201.51%-70.36%-76.08%-350.78%-151.19%-79.99%-48.84%
ROIC %
-
-
--27.3-23.5-26.3-41.3-15.9-21.7-114.6-26.5-21.2-6.8
OPM Ann. %
-
-
-26.51%-65.45%-67.59%-352.74%-------
Inventory Turnover Ratio Ann.
-
-
-2.22.71.2-------
Asset Turnover Ann. %
-
-
-0.70.60.2-------
Working Capital Turnover Ann.
115.4%
-
31.50.70.3
Quick Ratio Ann.
-
-
-23.52.53.87.991.32.85.118.3
Current Ratio Ann.
-
-
-2.13.62.53.87.991.42.95.318.6
Interest Coverage Ratio Ann.
-
-
--42.7-35.9-24.5-21.9-39.1-54.1-26.5-20.6-204.4-
LT Debt To Equity Ann.
-
-
-3.310.93.10.40.13.90.40.4-
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Axsome Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Cash From Operating Activity Axsome Therapeutics Inc Dec-2025 Cash From Operating Activity is $-93 Million which is growth of 27.3% YoY.

  • POSITIVE

    Net Cash Flow Axsome Therapeutics Inc Dec-2025 Net Cash Flow is $8 Million which is growth of 110.7% YoY.

Axsome Therapeutics Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-
-
-93.4-128.4-145.1-116.5-108.2-78.5-46.4-30.1-26.5-21.3-7.4
⌄
-
-
-0.5-0.3-0.6-53.7-0.3-0.1-0-0-0-0.1-0
⌄
-29.1%
19.1%
101.557.8331284.611.142.4252.41023.91052.9
Cash Plus Cash Eqv. End Of Year Ann.
17.2%
11.9%
322.9315.4386.2200.886.5183.9220143436.648
Net Increase In Cash Plus Cash Eqv.s Ann.
-59.5%
-
7.6-70.8185.4114.4-97.4-36.1206-20.1-2.6-11.445.4
Cash Plus Cash Eqv. Begin Of Year Ann.
53.9%
7.5%
315.4386.2200.886.5183.9220143436.6482.6
Income Tax Paid Supplemental Data Ann.
-
-
-----------
Interest Paid Supplemental Data Ann.
23.8%
47.4%
14.619.716.77.74.62.11.30.8---
Capex Ann.
-
-
-0.5-0.3-0.6-0.7-0.3-0.1-0-0-0-0.1-0
Issuance Of Capital Stock Ann.
-34.1%
36.9%
67.940.8258.8236.87.214.1238.212.923.7-45.6
Issuance Of Debt Ann.
94.3%
45.9%
33085455020107.4
Repayment Of Debt Ann.
-
-
-334.1-1--21.7-7.2-3.3-0.3--0
Repurchase Of Capital Stock Ann.
-
-
-----------
Free Cash Flow Ann.
-
-
-93.9-128.7-145.7-117.2-108.5-78.5-46.4-30.1-26.5-21.4-7.5
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
75.6%
2Y CAGR
-44.6%
3Y CAGR
-29.1%
5Y CAGR
19.1%
7Y CAGR
39.2%
10Y CAGR
6.7%
Cash from Financing Annual Activity growth is higher than historical averages.
×